St. Jude Research/Supplemental Data/ALL2/section A

A. PATIENT CHARACTERISTICS AND BONE MARROW SAMPLING TIMES

Fig. 1: Treatment regimen and bone marrow sampling times.

Bone marrow samples from children with acute lymphoblastic leukemia (ALL) were obtained at diagnosis (BM Pre-TX) and one day post-treatment (BM Post-TX) with mercaptopurine (MP) or high-dose methotrexate (HDMTX) given alone, or mercaptopurine in combination with either low-dose MTX (LDMTX+MP) or high-dose MTX (HDMTX+MP).

Table 1: Patient characteristics.

(a) The study included 60 pediatric patients with newly diagnosed ALL randomized to one of four initial treatments (“training set”). (b) Additionally, 17 new patients from the current protocol were included as an independent “test set”.

(a) treatment	n (n=60)	age at diagnosis (median in years)	sex	race	lineage	DNA ploidy	molecular translocations
MP	12	6.8	male: 7 female: 5	white: 10 black: 2 other: 0	B: 8 T: 4	hyperdiploid: 1 other: 11	MLL: 1 E2A-PBX: 0 TEL-AML: 1 BCR-ABL: 0 ND2: 10
HDMTX	22	6	male: 14 female: 8	white: 19 black: 1 other: 2	B: 19 T: 3	hyperdiploid: 4 other: 18	MLL: 0 E2A-PBX: 2 TEL-AML: 9 BCR-ABL: 0 ND2: 11
HDMTX+MP	10	5	male: 5 female: 5	white: 8 black: 1 other: 1	B: 8 T: 2	hyperdiploid: 0 other: 10	MLL: 2 E2A-PBX: 1 TEL-AML: 3 BCR-ABL: 0 ND2:4
LDMTX+MP	16	6.1	male: 13 female: 3	white: 12 black: 1 other: 3	B: 13 T: 3	hyperdiploid: 2 other: 14	MLL: 0 E2A-PBX: 0 TEL-AML: 4 BCR-ABL: 0 ND2: 12
P value¹		P=0.726	P=0.390	P=0.665	P=0.552	P=0.643	P=0.120

(b) treatment	n (n=17)	age at diagnosis (median in years)	sex	race	lineage	DNA ploidy	molecular translocations
HDMTX	17	5	male: 11 female: 6	white: 8 black: 5 other: 4	B: 13 T: 4	hyperdiploid: 8 other: 9	MLL: 0 E2A-PBX: 0 TEL-AML: 2 BCR-ABL: 1 ND2: 14

¹P value determined by Fisher’s exact test except Age by Wilcoxon’s rank sum test. 2ND=none detected